First dose-expansion patient successfully received SB-007 SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations SB-007 granted FDA Fast Track designation,...
Gilde Gilde Healthcare Portfolio company SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007 for Stargardt Disease
First dose-expansion patient successfully received SB-007 SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations SB-007 granted FDA Fast Track designation,...
9 januari 2026
Gilde Healthcare acquires a majority stake in Physio CKI, a physiotherapy practice group, from Kapital 1852
Gilde Healthcare's private equity fund announces the acquisition of a majority stake in Physio CKI from Kapital 1852. Physio CKI is a fast-growing group of physiotherapy practices headquartered in Cologne....
22 december 2025
Gilde Gilde Healthcare Portfolio company SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007 for Stargardt Disease
First dose-expansion patient successfully received SB-007 SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations SB-007 granted FDA Fast Track designation,...
9 januari 2026
Filter & zoek
Fonds strategie:
Loading...
Dit waren alle artikelen
30f80d5efe